EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Norway rat hepacivirus reporter for high-throughput quantification of neutralizing antibodies

Matthew J Kennedy iD, Raphael Wolfisberg iD, Emma A Lundsgaard iD, Caroline E Thorselius iD, Laura Collignon iD, Louise Nielsen, Kenn Holmbeck iD, Jens Bukh iD, Troels K H Scheel iD

Journal of Virology · 21.04.2026 · 100 (4)

DOI: 10.1128/jvi.01943-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 21.04.2026. Verfasst von Matthew J Kennedy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital and Department of Immunology and Microbiology, Universi…. Hauptthemen laut MEDLINE: Hepacivirus, Antibodies, Neutralizing, Genes, Reporter, Hepatitis C. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sundhed og Sygdom, Det Frie Forskningsråd, Novo Nordisk Fonden, Kræftens Bekæmpelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis C virus (HCV) remains a major global health challenge, with vaccine research hindered by a lack of robust immunocompetent animal models. Infection with the HCV-related Norway rat hepacivirus 1 (NrHV) in rats or mice shares HCV-defining characteristics, including chronicity, delayed immune responses, and liver disease, thereby providing immunocompetent small animal models for immune responses and pathology. Infectious NrHV cell culture systems allow studies of host factors and neutralizing antibodies; however, quantification relies on laborious manual counting of infected cells. To permit high-throughput quantification, we engineered culture-adapted NrHV to encode firefly luciferase (FLuc), green fluorescent protein (GFP), or the 11 amino acid HiBiT tag at sites corresponding to those permissive for HCV. While FLuc and GFP constructs were not viable, a reporter with a HiBiT insertion in the NS5A domain III was replication competent and produced infectious virus in rat hepatoma cells. Two mutations in NS5A adapted this virus to levels comparable to wild type, enabling robust luciferase readouts. The NrHV-HiBiT-NS5A reporter was stable, viable in rats, and permitted quantification of luciferase from liver homogenates. Luciferase-based quantification of viral infection after antibody neutralization correlated well with manual quantification. High-throughput luciferase quantification was also used to confirm dependency on the known host factors SR-BI and miR-122 and to assess sensitivity to antivirals. Finally, sensitivity to a specific inhibitor suggested that cyclophilin A, similarly to HCV, may be a host factor for NrHV. This novel reporter system could accelerate characterization of the NrHV model as well as ongoing vaccine studies for HCV. IMPORTANCE Direct-acting antiviral therapy provides an effective cure for chronic hepatitis C virus (HCV) infection, but the infection burden remains high due to cost and availability of therapy and low diagnosis rates. A vaccine, therefore, is critical for global control of viral transmission; however, vaccine development is constrained by a lack of robust immunocompetent animal models. Norway rat hepacivirus 1 (NrHV) infection of rats and mice serves as an effective small animal model for HCV, permitting evaluation of vaccine platforms and candidates. Neutralizing antibody responses are considered crucial for protection and can be quantified using the NrHV cell culture system, however, only through laborious low-throughput methods. We here present an NrHV reporter virus allowing high-throughput quantification of antibody neutralization, virus-host interactions, and antiviral efficacy via luciferase readout. This reporter will facilitate characterization of NrHV and support ongoing vaccine research with the potential for global control of HCV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepacivirusAntibodies, NeutralizingGenes, ReporterHepatitis CHepatitis C AntibodiesAnimalsRatsViral Nonstructural ProteinsRNA-Dependent RNA PolymeraseHigh-Throughput Screening AssaysDisease Models, AnimalGreen Fluorescent ProteinsHumans

Stichwörter der Autor:innen

animal modelhepacivirushepatitis C virusneutralizing antibodiesreporter virusvirus-host interactions

Substanzen

Antibodies, NeutralizingViral Nonstructural ProteinsRNA-Dependent RNA PolymeraseHepatitis C AntibodiesGreen Fluorescent ProteinsNS-5 protein, hepatitis C virus

Autor:innen und Institutionen

  • Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital and Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Matthew J Kennedy, Raphael Wolfisberg, Emma A Lundsgaard, Caroline E Thorselius, Laura Collignon, Kenn Holmbeck, Jens Bukh, Troels K H Scheel

Förderung

  • Sundhed og Sygdom, Det Frie Forskningsråd
  • Novo Nordisk Fonden
  • Kræftens Bekæmpelse
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Kennedy, M. J., Wolfisberg, R., Lundsgaard, E. A., Thorselius, C. E., Collignon, L., Nielsen, L., Holmbeck, K., Bukh, J., & Scheel, T. K. H. (2026). Development of a Norway rat hepacivirus reporter for high-throughput quantification of neutralizing antibodies. Journal of Virology, 100(4). https://doi.org/10.1128/jvi.01943-25

Vancouver

Kennedy MJ, Wolfisberg R, Lundsgaard EA, Thorselius CE, Collignon L, Nielsen L, et al. Development of a Norway rat hepacivirus reporter for high-throughput quantification of neutralizing antibodies. Journal of Virology. 2026;100(4). doi:10.1128/jvi.01943-25

BibTeX
@article{Kennedy2026,
  author = {Kennedy, Matthew J and Wolfisberg, Raphael and Lundsgaard, Emma A and Thorselius, Caroline E and Collignon, Laura and Nielsen, Louise and Holmbeck, Kenn and Bukh, Jens and Scheel, Troels K H},
  title = {Development of a Norway rat hepacivirus reporter for high-throughput quantification of neutralizing antibodies},
  journal = {Journal of Virology},
  year = {2026},
  volume = {100},
  number = {4},
  doi = {10.1128/jvi.01943-25}
}
Kostenlos starten →